Semaglutide has been shown to reduce major adverse cardiovascular events in patients with established cardiovascular disease and overweight or obesity without diabetes; however, its effect on hospitalization outcomes is less well defined. To address this gap, a study evaluated the impact of semaglutide on total hospital admissions and length of hospital stay in patients with established cardiovascular disease, involving 17,604 participants, median age, 61.0 years. The study found that semaglutide significantly reduced hospitalization burden compared with placebo.
Total hospitalizations for any indication occurred at rates of 18.3 vs 20.4 admissions per 100 patient-years (mean ratio [MR], 0.90), while hospitalizations for serious adverse events occurred at 15.2 vs 17.1 admissions per 100 patient-years (MR, 0.89). Similarly, days hospitalized were lower with semaglutide for any indication…
